PT3077544T - Projeto baseado em fundamentos de uma terapia alvo para 0 cancro - Google Patents

Projeto baseado em fundamentos de uma terapia alvo para 0 cancro

Info

Publication number
PT3077544T
PT3077544T PT14867137T PT14867137T PT3077544T PT 3077544 T PT3077544 T PT 3077544T PT 14867137 T PT14867137 T PT 14867137T PT 14867137 T PT14867137 T PT 14867137T PT 3077544 T PT3077544 T PT 3077544T
Authority
PT
Portugal
Prior art keywords
rationale
cancer
targeted therapy
based design
design
Prior art date
Application number
PT14867137T
Other languages
English (en)
Inventor
J Lee Allen
J Lee Jason
m lu David
Lee Ruey-Min
Original Assignee
Celestra Life Science Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celestra Life Science Llc filed Critical Celestra Life Science Llc
Publication of PT3077544T publication Critical patent/PT3077544T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT14867137T 2013-12-03 2014-12-03 Projeto baseado em fundamentos de uma terapia alvo para 0 cancro PT3077544T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361911423P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
PT3077544T true PT3077544T (pt) 2019-08-01

Family

ID=53274072

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14867137T PT3077544T (pt) 2013-12-03 2014-12-03 Projeto baseado em fundamentos de uma terapia alvo para 0 cancro

Country Status (9)

Country Link
US (2) US9782418B2 (pt)
EP (1) EP3077544B1 (pt)
CN (1) CN106029905B (pt)
AU (1) AU2014360503A1 (pt)
DK (1) DK3077544T3 (pt)
ES (1) ES2732445T3 (pt)
LT (1) LT3077544T (pt)
PT (1) PT3077544T (pt)
WO (1) WO2015084958A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732445T3 (es) * 2013-12-03 2019-11-22 Celestra Life Science Llc Diseño basado en la racionalidad de una terapia específica para el cáncer
CN108220242A (zh) * 2016-12-10 2018-06-29 中国科学院大连化学物理研究所 Spop及突变体表达的c4-2稳定细胞系及构建方法
CN107299133A (zh) * 2017-06-09 2017-10-27 上海长海医院 一种前列腺癌的标志物spop及其在指导肿瘤治疗中的应用
CN110396544B (zh) * 2019-06-19 2021-12-24 山东大学齐鲁医院 Cul7在胶质瘤诊断、治疗和预后中的应用
WO2021007512A1 (en) * 2019-07-11 2021-01-14 Emory University Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (gr) binding agents, and/or hsp90 binding agents for uses in treating cancer
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN110970087B (zh) * 2019-12-31 2021-08-03 华中科技大学 一种鉴定调控细胞自噬的功能激酶的方法
CN111671760A (zh) * 2020-06-10 2020-09-18 谭志荣 人参皂苷ck在制备抗结直肠癌药物中的应用
KR20230093329A (ko) 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
JP7657583B2 (ja) * 2020-12-16 2025-04-07 株式会社東芝 核酸構築物、キット、検出方法及び治療効果予測方法
CN119303100A (zh) * 2024-12-12 2025-01-14 宁波大学 Parp抑制剂联合spop抑制剂或ck2抑制剂在制备前列腺癌抑制剂中的应用
CN120053653A (zh) * 2025-02-27 2025-05-30 华东师范大学 Ncoa家族蛋白的组蛋白琥珀酰化修饰酶活性作为药物靶点在制备预防/治疗/诊断肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489562B (zh) * 2006-07-21 2012-04-18 赛福伦公司 用于治疗脊髓增生病的jak抑制剂
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MY150379A (en) * 2008-02-26 2013-12-31 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
DE102008031699A1 (de) * 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
WO2011066344A1 (en) * 2009-11-25 2011-06-03 Dana-Farber Cancer Institute, Inc. Crlf2 in precursor b-cell acute lymphoblastic leukemia
WO2012092339A2 (en) * 2010-12-28 2012-07-05 The Children's Hospital Of Philadelphia The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations
ES2732445T3 (es) * 2013-12-03 2019-11-22 Celestra Life Science Llc Diseño basado en la racionalidad de una terapia específica para el cáncer

Also Published As

Publication number Publication date
LT3077544T (lt) 2019-07-10
US9782418B2 (en) 2017-10-10
AU2014360503A1 (en) 2016-06-30
CN106029905B (zh) 2020-04-14
EP3077544A4 (en) 2017-07-05
WO2015084958A1 (en) 2015-06-11
EP3077544A1 (en) 2016-10-12
US10449202B2 (en) 2019-10-22
CN106029905A (zh) 2016-10-12
US20180117061A1 (en) 2018-05-03
ES2732445T3 (es) 2019-11-22
US20160303140A1 (en) 2016-10-20
EP3077544B1 (en) 2019-04-24
DK3077544T3 (da) 2019-07-08

Similar Documents

Publication Publication Date Title
IL245731A0 (en) Combined treatment for cancer
IL241232A0 (en) Cancer treatment agents
GB201322725D0 (en) Cancer therapy
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
LT3077544T (lt) Racionalia logika pagrįstas tikslinės vėžio terapijos modelis
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
IL241101A0 (en) Medicinal uses of empagliflozin
HUE060721T2 (hu) Empagliflozin terápiás alkalmazásai
HUE041709T2 (hu) Az empagliflozin terápiás alkalmazásai
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
SG11201509707QA (en) Cancer therapy
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
SG11201507847UA (en) Cancer therapy
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
EP2961412A4 (en) CANCER THERAPY
GB201310755D0 (en) Therapy
GB201403083D0 (en) Treatment of cancer
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201308039D0 (en) Photodynamic therapy
GB201518731D0 (en) Tumour Therapy
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201217890D0 (en) Treatment of cancer
GB201317213D0 (en) Cancer Therapy